#Semaglutide

NA-931 Cuts Weight Without Major Muscle Loss in Mid-Stage Trial

NA-931 Cuts Weight Without Major Muscle Loss in Mid-Stage Trial

An experimental oral medicine called NA-931 led to substantial weight loss with only modest reductions in lean mass in a randomized phase II trial. Researchers from developer Biomed Industries presented the topline results at the ObesityWeek annual meeting. The highest doses reduced body weight by 13.8% and 11.3% at week 13, compared with 1.9% on placebo. Lean mass fell by 1.7% over the same period, and nausea rates were only slightly higher than placebo. The company says it is advancing NA-931 into phase III testing. The findings are early and come from a small study of 125 adults.

FDA Adds Vision Loss Warning to GLP-1 Drugs, Leaving Doctors and Patients With Hard Choices

FDA Adds Vision Loss Warning to GLP-1 Drugs, Leaving Doctors and Patients With Hard Choices

The FDA will require new warnings across the entire GLP-1 drug class about a possible increased risk of NAION, a rare condition that damages the optic nerve and can cause permanent vision loss. The class includes Ozempic, Wegovy, Zepbound and Mounjaro. Because the drugs are widely used, the warning forces a difficult question: when a patient develops NAION, should treatment stop? Regulators in Europe and the U.S. have answered differently. An ophthalmologist who has asked patients about GLP-1 use for two years says the FDA should now study what happens after a diagnosis, and that patients cannot wait years for answers.

Two Case Reports Link Abrupt Tirzepatide Discontinuation to Mania and Psychosis

Two Case Reports Link Abrupt Tirzepatide Discontinuation to Mania and Psychosis

Two men were hospitalized with acute psychiatric symptoms after abruptly stopping tirzepatide, the active ingredient in Mounjaro and Zepbound, according to case studies published in The Primary Care Companion for Central Nervous System Disorders. One patient showed signs of psychosis, including hallucinations and a rare delusion that he was dead, while the other was diagnosed with a manic episode. The authors do not claim the drug withdrawal caused the symptoms. They say the timing is worth attention and that prescribers should consider recent changes in GLP-1 medication when evaluating patients with new mood or psychotic symptoms.

Wegovy Cuts BMI in Children With Obesity as Young as 6, Trial Finds

Wegovy Cuts BMI in Children With Obesity as Young as 6, Trial Finds

Wegovy (semaglutide) significantly reduced body mass index in children ages 6 to 11 with obesity, according to results from the phase III STEP Young trial. Presented at the ObesityWeek annual meeting and published in the New England Journal of Medicine, the study found that treated children lost weight while placebo patients gained it. Researchers also reported slower height gain and frequent gastrointestinal side effects. Drugmaker Novo Nordisk has not said whether it will submit the data to the FDA.

Cheaper GLP-1 Generics Arrive, and a Global Access Fight May Follow

Cheaper GLP-1 Generics Arrive, and a Global Access Fight May Follow

Lower-cost generic versions of semaglutide, the drug sold as Wegovy by Novo Nordisk for obesity, have begun reaching some countries and will soon arrive in others. At the same time, drugmakers are racing to develop newer GLP-1 medicines that are forecast to be more effective, cause fewer side effects and be easier to administer. London School of Economics professor Ken Shadlen, who studies the politics of pharmaceutical and health regulation, warns that obesity medications could become the next major battleground over access to medicines in lower-income countries. The shifts could put weight-loss treatment within reach of more people, but the path to access is far from settled.

Tirzepatide Cuts BMI Sharply in Adolescents With Obesity, Phase III Trial Finds

Tirzepatide Cuts BMI Sharply in Adolescents With Obesity, Phase III Trial Finds

Tirzepatide (Zepbound) produced substantial reductions in body mass index among adolescents with obesity in the phase III SURMOUNT-ADOLESCENTS trial. At week 72, participants on the once-weekly GLP-1/GIP drug alongside a healthy lifestyle program saw an 18.5% mean BMI reduction, while those on placebo saw a 0.5% increase. The trial met its primary endpoint, and all 10 key secondary outcomes also favored tirzepatide. Results were presented at the ObesityWeek annual meeting and published in JAMA. The researchers cautioned against escalating doses to the maximum tolerated level in routine care.

Hundreds of English Children Prescribed Weight-Loss Jabs, Figures Show

Hundreds of English Children Prescribed Weight-Loss Jabs, Figures Show

Hundreds of children in England are receiving prescriptions for GLP-1 medications, including some under 12, according to a Guardian investigation of NHS prescribing data. In the 2025-26 financial year, 419 prescriptions were issued to under-18s, 10 of them to children under 12. Experts say the figures likely understate the true total, and they stress that children who start these drugs need specialist supervision and long-term monitoring. The findings come as childhood obesity rates continue to rise and as new global guidance advises against giving obesity medications to children under 10.